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Adult T cell leukemia/lymphoma (ATL) and HTLV-1-
associated myelopathy/tropical spastic paraparesis
(HAM/TSP) are caused by HTLV-I infection. In these
patients, the antibody titer and provirus load are ele-
vated compared to levels in asymptomatic carriers (AC).
These methods that determine HTLV-I infection do not
differentiate between AC, HAM/TSP patients, and ATL
patients. We have reported on a Luciferase Immunopre-
cipitation System (LIPS), a highly sensitive, quantitative
technology that can efficiently detect HTLV-I antibody
responses in serum of infected individuals [1]. We
extended our preliminary analysis to detect anti-HTLV-I
antibodies in samples from 439 persons from Jamaica:
normal donors (ND), AC, ATL, and HAM/TSP patients.
The antibody responses of ND differed significantly
from those of HTLV-I infected patients for all three
immunodominant proteins. More specifically, HAM/
TSP patients were 2 times more likely to have an anti-
body response >1 standard deviation above the mean for
ACs in gag (Odds Ratio (OR) = 2.45, 95% confidence
interval [CI] = 1.23-4.88) and were 5 times more likely
to exceed that threshold in env (OR = 5.27, CI = 2.51-
11.08). ATL patients were 1.8 times more likely to
exceed that threshold in env (OR = 1.82, CI = 1.01-3.27)
and 70% less likely to exceed that threshold in tax (OR
= 0.30, CI = 0.11-0.51). HAM/TSP patients had signifi-
cantly higher antibody responses in gag, env, and tax
compared to ATL patients. These significant differences
between antibody responses in HTLV-I infected indivi-
duals may be a useful diagnostic tool in the future.
Author details
1Neuroimmunology Branch, National Institute of Neurological Diseases and
Stroke, National Institutes of Health, Bethesda, MD, USA.
2Infections and
Immunoepidemiology Branch, National Cancer Institute, Bethesda, MD, USA.
3Division of Epidemiology, Food and Drug Administration, Silver Spring, MD,
USA.
Published: 6 June 2011
Reference
1. Burbelo P, Meoli E, Leahy H, Graham J, Yao K, Oh U, Janik J, Mahieux R,
Kashanchi F, Iadarola M, Jacobson S: Anti-HTLV antibody profiling reveals
an antibody signature for HTLV-I-Associated Myelopathy/Tropical Spastic
Paraparesis (HAM/TSP). Retrovirology 2008, 5:96.
doi:10.1186/1742-4690-8-S1-A110
Cite this article as: Akahata et al.: Quantitative differences in antibody
responses between normal donors HAM/TSP patients, asymptomatic
carriers, and ATL patients from Jamaica: can they be used to estimate
risk of disease? Retrovirology 2011 8(Suppl 1):A110.
* Correspondence: abramsan@mail.nih.gov
1Neuroimmunology Branch, National Institute of Neurological Diseases and
Stroke, National Institutes of Health, Bethesda, MD, USA
Full list of author information is available at the end of the article
Akahata et al. Retrovirology 2011, 8(Suppl 1):A110
http://www.retrovirology.com/content/8/S1/A110
© 2011 Akahata et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.